Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug access
Pharma
How biosimilar developers are embracing next phase of US market
Although the so-called biosimilar ‘void’ could pose challenges to upcoming biosimilar availability, the opportunity it presents is also immense.
Zoey Becker
,
Fraiser Kansteiner
Jul 6, 2026 10:03am
Colorado wins FDA approval to import cheaper drugs from Canada
Jun 17, 2026 10:30am
MSF decries Gilead's updated global access plan for Yeztugo
Apr 15, 2026 12:14pm
Manufacturing is key to Gilead's Yeztugo PrEP rollout: exec
Mar 13, 2026 10:33am
Clear prices, e-commerce experience a must for pharma DTP sites
Mar 10, 2026 12:56pm
HCPs have mixed feelings on pharma DTP platforms: survey
Jan 5, 2026 12:11pm